Does high serum iron level induce low bone mass in sickle cell anemia ?

BioMetals ◽  
2010 ◽  
Vol 24 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Mir Sadat-Ali ◽  
Osama Sultan ◽  
Haifa Al-Turki ◽  
Abdulmohsen AlElq
Keyword(s):  
Bone Mass ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Serum Iron ◽  
High Serum ◽  
Iron Level ◽  
Low Bone Mass ◽  
Serum Iron Level

scholarly journals Oxymetholone treatment for sickle cell anemia

Blood ◽  
1975 ◽  
Vol 45 (6) ◽  
pp. 769-777 ◽  
Author(s):  
R Alexanian ◽  
J Nadell
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Cell Mass ◽  
Iron Level ◽  
Red Cell ◽  
Bilirubin Concentration ◽  
Serum Iron Level ◽  
Control Value ◽  
Red Cell Mass ◽  
Androgenic Hormone

Abstract Seven patients with sickle cell anemia were treated with oxymetholone for at least 2 mo. Markedly increased basal rates of hemolysis and erythropoiesis were confirmed. The urinary erythropoietin excretion was either normal or lower than expected for the red cell mass, and an expanded blood volume was due primarily to an increased plasma volume. After androgen therapy, six patients demonstrated more than a fivefold increase in urinary erythropoietin, with an increase in red cell mass ranging from 17%-75% above the control value. All showed a decline in serum iron level to the 25–75 mug/100 ml range within 4 wk after the start of therapy. Less marked changes followed lower oxymetholone doses. Reversible hepatic toxicity, with a serum bilirubin concentration exceeding 50 mg/100 ml, occurred in one patient. Androgenic hormone therapy may be useful for selected adult patients with sickle cell disease when severe anemia contributes to disease morbidity.

Correlation of Iron Levels with Asthma and Lung Function in Pediatric Patients with Sickle Cell Anemia

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 12-12
Author(s):  
Yusra D Shaikh ◽  
Nataly Apollonsky ◽  
Bruce Bernstein
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Serum Iron ◽  
Pediatric Patients ◽  
Pulmonary Complications ◽  
Acute Chest Syndrome ◽  
Iron Level ◽  
Obstructive Sleep ◽  
History Of ◽  
Hb S

Introduction:Significant morbidity and mortality in patients with sickle cell disease (SCD) is attributed to the pulmonary sequalae of the disease. Patients with SCD often suffer airway hyper-reactivity, acute chest syndrome (ACS), chronic lung disease, pulmonary hypertension (PHTN), and obstructive sleep apnea (OSA). Recent literature has provided evidence supporting the strong association between asthma and airway hyper-reactivity in SCD. One of the factors linked to chronic inflammation and asthma is iron status. The present study examined whether iron levels are associated with pulmonary complications in pediatric patients with SCD. Method:Through retrospective review of electronic medical records (EMR) we evaluated patients with diagnosis of asthma and SCD. All patients with available PFT (3/21/2013-3/11/2020) and iron studies were included in the analysis. Chi square and ANOVA tests were used to explore relationships of respiratory conditions with lab data and relevant medical history. Results:The analysis reviewed information of 100 patients with SCD -- 56 males and 44 females The sample population had the following genotypes: 63% Hemoglobin (Hb) SS, 23% Hb SC, 2% Hb S Beta Zero Thalassemia, and 12% Hb S Beta Thalassemia. 38% of these patients were receiving treatment via hydroxyurea. The results generated found that patients with a large airway obstruction (LAO) had a marginally statistically significantly higher serum iron level than those with no LAO (p=0.067.) Patients with homozygous Hb S disease were four times as likely to have a history of ACS (p=0.004) than those without and were marginally significantly more likely to be SS and SB0Thal (p=0.052). Patients with history of ACS had a significantly higher mean iron saturation and lower total iron binding capacity (TIBC.) Patients with PHTN had significantly higher serum iron levels (p=0.029). Conclusion:Our findings reveal that while iron might play a more significant role in the development of PHTN and ACS in patients with SCD, the role in asthma is borderline in our sample. These findings, although of borderline statistical significance p=0.067, are clinically noteworthy. These results may open a new window for therapy targeted at maintaining iron in normal physiologic ranges to decrease pulmonary complications in patients with sickle cell anemia. Further studies with larger samples are necessary to clarify the meaning of our marginally significant findings. Disclosures No relevant conflicts of interest to declare.

Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15110-e15110
Author(s):  
T. Ochiai ◽  
K. Nishimura ◽  
T. Watanabe ◽  
M. Kitajima ◽  
N. Nakayama ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Serum Iron ◽  
Biological Response ◽  
Serum Levels ◽  
High Serum ◽  
Iron Level ◽  
Iron Group ◽  
Survival Times ◽  
High Increase ◽  
Serum Iron Level

e15110 Background: The alteration of serum-iron level during chemotherapy is already reported (Follezou, NEOPLASMA 1985). However, the correlation to prognosis has not been evaluated. The aim of this study was to evaluate the correlation between prognosis and serum-iron level in advanced / metastatic colorectal cancer (aCRC / mCRC) patients treated by FOLFOX / FOLFIRI. Methods: Serum-iron levels, hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were analyzed in 58 aCRC / mCRC patients received FOLFOX-4 / FOLFIRI therapy between April 2005 and September 2008. 26 patients received FOLFOX-4 / FOLFIRI therapy as the final chemotherapy died by the time of analysis. These patients were categorized into the high increase group and the low increase group using 200% increase as cut-off value and the prognosis was compared. Results: Mean serum-iron levels in immediately pre and post chemotherapy were 71.7±29.0μg/dl and 186.8±83.2μg/dl, respectively, and significant increase after chemotherapy was observed (p<0.001). This increase was transient and returns to pre chemotherapy level by the start of next course. This alteration was always observed on the chemotherapy. The median survival times from the initiation of FOLFOX-4 / FOLFIRI therapy for the high increase group (n: 5) and the low increase group (n: 21) were 487 and 182 days, respectively, and was significantly better in the high increase group (p=0.004). The alterations of hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were not observed. Conclusions: It is suggested that serum-iron increase is a biological response not attributed to leakage from erythrocyte and hepatocyte. Significantly better prognosis in high serum-iron group may suggest the usefulness of serum-iron level to distinguish responder and non-responder in FOLFOX-4/FOLFIRI therapy. No significant financial relationships to disclose.

scholarly journals High Serum Iron level is Associated with Increased Mortality in Patients with Sepsis

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Peng Lan ◽  
Kong-han Pan ◽  
Shuo-jia Wang ◽  
Qiu-cheng Shi ◽  
Yun-xian Yu ◽  
...  
Keyword(s):  
Serum Iron ◽  
High Serum ◽  
Iron Level ◽  
Serum Iron Level

scholarly journals Oxymetholone treatment for sickle cell anemia

Blood ◽  
1975 ◽  
Vol 45 (6) ◽  
pp. 769-777
Author(s):  
R Alexanian ◽  
J Nadell
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Cell Mass ◽  
Iron Level ◽  
Red Cell ◽  
Bilirubin Concentration ◽  
Serum Iron Level ◽  
Control Value ◽  
Red Cell Mass ◽  
Androgenic Hormone

Seven patients with sickle cell anemia were treated with oxymetholone for at least 2 mo. Markedly increased basal rates of hemolysis and erythropoiesis were confirmed. The urinary erythropoietin excretion was either normal or lower than expected for the red cell mass, and an expanded blood volume was due primarily to an increased plasma volume. After androgen therapy, six patients demonstrated more than a fivefold increase in urinary erythropoietin, with an increase in red cell mass ranging from 17%-75% above the control value. All showed a decline in serum iron level to the 25–75 mug/100 ml range within 4 wk after the start of therapy. Less marked changes followed lower oxymetholone doses. Reversible hepatic toxicity, with a serum bilirubin concentration exceeding 50 mg/100 ml, occurred in one patient. Androgenic hormone therapy may be useful for selected adult patients with sickle cell disease when severe anemia contributes to disease morbidity.

scholarly journals A High Serum Iron Level Causes Mouse Retinal Iron Accumulation Despite an Intact Blood-Retinal Barrier

2014 ◽  
Vol 184 (11) ◽  
pp. 2862-2867 ◽  
Author(s):  
Liangliang Zhao ◽  
Yafeng Li ◽  
Delu Song ◽  
Ying Song ◽  
Milan Theurl ◽  
...  
Keyword(s):  
Serum Iron ◽  
High Serum ◽  
Iron Accumulation ◽  
Iron Level ◽  
Blood Retinal Barrier ◽  
Serum Iron Level

scholarly journals Author Correction: The U‑shaped association of serum iron level with disease severity in adult hospitalized patients with COVID‑19

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kentaro Tojo ◽  
Yoh Sugawara ◽  
Yasufumi Oi ◽  
Fumihiro Ogawa ◽  
Takuma Higurashi ◽  
...  
Keyword(s):  
Disease Severity ◽  
Serum Iron ◽  
Hospitalized Patients ◽  
Iron Level ◽  
Serum Iron Level

scholarly journals ROLE OF SERUM IRON AND ITS ASSOCIATION WITH ANEMIC PREVALANCE AMONG PATIENTS WITH DIFFERENT TYPE OF CANCER

2017 ◽  
Vol 5 (5(SE)) ◽  
pp. 37-41
Author(s):  
Andrew Pradeep M ◽  
Indira G ◽  
Sethu Nagarajan R
Keyword(s):  
Iron Deficiency ◽  
Serum Iron ◽  
Physiological Activity ◽  
Iron Concentration ◽  
Active Role ◽  
Control Individual ◽  
Iron Level ◽  
Serum Iron Level ◽  
Immune Effector ◽  
Patients With Cancer

Cancer is a group of diseases in which cells are aggressive, invasive and sometimes metastatic. Nutritional status an important factor that contributes to immune competence for which trace minerals plays a crucial role in the biochemical and physiological activity of the system. Trace element a category of minerals essential for the biological system and plays an active role in immune effector mechanism.  Normal range of iron essential for body metabolism, iron deficiencies leads to anemia which might complicate the event of tumor genesis. Study involved 50 volunteers (36 females, 14 males) of cancer patients of Mohan Nursing Home Madurai. Serum was collected in the informed consent of the patients. Serum iron level was quantified using Atomic Absorption Spectrophotometer. Study documented percentage deviation of serum iron concentration (85%) with severe anemic prevalence from the control individual (without cancer) and also establish an association of iron deficiency with anemic prevalence. Study documented the existence of Iron deficiency which is the most common cause of anemia worldwide. Iron plays a role in oxygen transfer in cytochromes, protein molecules involved in the production of energy in cells and also exhibit certain properties to facilitate antitumor status. Study concludes that serum iron modulations need to be emphasized to minimize the burdenization of the host with Clinical associated complications of Iron deficiency among patients with cancer.

The Potential Clinical Significance of the Serum Iron and Ferritin Status in Lung Cancer Patients

2020 ◽  
Vol 5 (4) ◽  
pp. 189-195
Author(s):  
Fei Fei Guo ◽  
◽  
Shi Jia Cheng ◽  
Yi Ning Liu ◽  
Jiu Wei Cui ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Serum Ferritin ◽  
Serum Iron ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Stage Iv ◽  
Iron Level ◽  
Serum Iron Level ◽  
Lung Cancer Patients

Background An increasing number of studies have shown that iron, one of the indispensable trace elements in the human body, is closely related to the occurrence and development of cancer. However, few studies have clearly demonstrated the role of the iron levels in lung cancer patients, or the potential effects of inflammation on iron levels. Methods The clinical data for lung cancer patients and non-lung cancer participants were retrospectively analyzed. The serum iron and ferritin levels were measured and compared using a rank-sum test. The correlation between the serum iron/ferritin and C-reactive protein (CRP) was analyzed by rank correlation. The cut-off values for continuous variables were obtained by the receiver operating characteristic curve (ROC) method. An analysis of potential prognostic factors in lung cancer patients was conducted by univariate and multivariate survival analyses. Results The serum iron levels in patients with extensive small-cell lung cancer (SCLC) were lower than those with limited-stage SCLC, and the levels of serum ferritin and CRP in those with extensive SCLC were higher than those with limited-stage SCLC. Similarly, the serum iron levels in patients with stage IV non-small cell lung cancer (NSCLC) were lower than those of patients with stage Ⅰ-Ⅲ disease, and the levels of serum ferritin and CRP in those with stage IV NSCLC were higher than those in stages Ⅰ-Ⅲ. The serum iron level was negatively correlated with the level of CRP, while the serum ferritin level was positively correlated with CRP. The stage of lung cancer, but not the serum iron/ ferritin level, was an independent prognostic factor in lung cancer patients. Conclusions The serum iron and ferritin levels are associated with the staging of lung cancer. The later stages of lung cancer are associated with a lower serum iron level, a higher serum ferritin level, and a higher CRP level. Inflammation may play an important role in regulating the serum iron and ferritin levels in lung cancer patients.

Sign in / Sign up

Export Citation Format

Share Document